The invention encompasses novel N-alkyl-hydroxamic acid-isoindolyl
compounds, pharmaceutical compositions of these compounds, and methods of
using these compounds and compositions for treatment or prevention of
various diseases and disorders, for example, diseases associated with
PDE4.